BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Titze-de-Almeida R, David C, Titze-de-Almeida SS. The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. Pharm Res 2017;34:1339-63. [PMID: 28389707 DOI: 10.1007/s11095-017-2134-2] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Tawfik M, Chen F, Goldberg JL, Sabel BA. Nanomedicine and drug delivery to the retina: current status and implications for gene therapy. Naunyn-Schmiedeberg's Arch Pharmacol. [DOI: 10.1007/s00210-022-02287-3] [Reference Citation Analysis]
2 Paul A, Muralidharan A, Biswas A, Venkatesh Kamath B, Joseph A, Alex AT. siRNA Therapeutics and its Challenges: Recent Advances in Effective Delivery for Cancer Therapy. OpenNano 2022. [DOI: 10.1016/j.onano.2022.100063] [Reference Citation Analysis]
3 Chan KYY, Chung PY, Zhang C, Poon ENY, Leung AWK, Leung KT. R4 RGS proteins as fine tuners of immature and mature hematopoietic cell trafficking. J Leukoc Biol 2022. [PMID: 35694792 DOI: 10.1002/JLB.1MR0422-475R] [Reference Citation Analysis]
4 Merkel OM. Can pulmonary RNA delivery improve our pandemic preparedness? Journal of Controlled Release 2022;345:549-56. [DOI: 10.1016/j.jconrel.2022.03.039] [Reference Citation Analysis]
5 Prakash G, Shokr A, Willemen N, Bashir SM, Shin SR, Hassan S. Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids. Adv Drug Deliv Rev 2022;184:114197. [PMID: 35288219 DOI: 10.1016/j.addr.2022.114197] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gangopadhyay S, Gore KR. Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications. RNA Biology 2022;19:452-67. [DOI: 10.1080/15476286.2022.2052641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
7 Andersson P. Preclinical Safety Assessment of Therapeutic Oligonucleotides. Methods Mol Biol 2022;2434:355-70. [PMID: 35213031 DOI: 10.1007/978-1-0716-2010-6_25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev 2022;182:114113. [PMID: 35063535 DOI: 10.1016/j.addr.2022.114113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
9 Milan A, Mioc A, Prodea A, Mioc M, Buzatu R, Ghiulai R, Racoviceanu R, Caruntu F, Şoica C. The Optimized Delivery of Triterpenes by Liposomal Nanoformulations: Overcoming the Challenges. Int J Mol Sci 2022;23:1140. [PMID: 35163063 DOI: 10.3390/ijms23031140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Belostotsky R, Frishberg Y. Catabolism of Hydroxyproline in Vertebrates: Physiology, Evolution, Genetic Diseases and New siRNA Approach for Treatment. Int J Mol Sci 2022;23:1005. [PMID: 35055190 DOI: 10.3390/ijms23021005] [Reference Citation Analysis]
11 Asimgil H, Ertetik U, Çevik NC, Ekizce M, Doğruöz A, Gökalp M, Arık-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE. Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 2022;7:e153688. [PMID: 35014625 DOI: 10.1172/jci.insight.153688] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
12 Zhang Y, Wang Y, Su X, Wang P, Lin W. The Value of Circulating Circular RNA in Cancer Diagnosis, Monitoring, Prognosis, and Guiding Treatment. Front Oncol 2021;11:736546. [PMID: 34722285 DOI: 10.3389/fonc.2021.736546] [Reference Citation Analysis]
13 Wang P, Zhou Y, Richards AM. Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry. Theranostics 2021;11:8771-96. [PMID: 34522211 DOI: 10.7150/thno.62642] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
14 Zhang X, Lin ZI, Yang J, Liu GL, Hu Z, Huang H, Li X, Liu Q, Ma M, Xu Z, Xu G, Yong KT, Tsai WC, Tsai TH, Ko BT, Chen CK, Yang C. Carbon Dioxide-Derived Biodegradable and Cationic Polycarbonates as a New siRNA Carrier for Gene Therapy in Pancreatic Cancer. Nanomaterials (Basel) 2021;11:2312. [PMID: 34578632 DOI: 10.3390/nano11092312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wu L, Zhou W, Lin L, Chen A, Feng J, Qu X, Zhang H, Yue J. Delivery of therapeutic oligonucleotides in nanoscale. Bioact Mater 2022;7:292-323. [PMID: 34466734 DOI: 10.1016/j.bioactmat.2021.05.038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
16 Thomas CN, Bernardo-Colón A, Courtie E, Essex G, Rex TS, Blanch RJ, Ahmed Z. Effects of intravitreal injection of siRNA against caspase-2 on retinal and optic nerve degeneration in air blast induced ocular trauma. Sci Rep 2021;11:16839. [PMID: 34413361 DOI: 10.1038/s41598-021-96107-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Berger M, Lechanteur A, Evrard B, Piel G. Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now? Int J Pharm 2021;605:120851. [PMID: 34217823 DOI: 10.1016/j.ijpharm.2021.120851] [Reference Citation Analysis]
18 Nanbo A, Furuyama W, Lin Z. RNA Virus-Encoded miRNAs: Current Insights and Future Challenges. Front Microbiol 2021;12:679210. [PMID: 34248890 DOI: 10.3389/fmicb.2021.679210] [Reference Citation Analysis]
19 Zhang Z, Heng Y, Cheng W, Pan Y, Ni S, Li H. Reactive oxygen species (ROS)-response nanomedicine through knocking down a novel therapeutic target NEDD8-conjugating enzyme UBC12 (UBE2M) in the treatment of liver cancer. Materials & Design 2021;204:109648. [DOI: 10.1016/j.matdes.2021.109648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
20 Sang R, Stratton B, Engel A, Deng W. Liposome technologies towards colorectal cancer therapeutics. Acta Biomater 2021;127:24-40. [PMID: 33812076 DOI: 10.1016/j.actbio.2021.03.055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Cordes F, Demmig C, Bokemeyer A, Brückner M, Lenze F, Lenz P, Nowacki T, Tepasse P, Schmidt HH, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.Clin Transl Gastroenterol. 2020;11:e00134. [PMID: 32352717 DOI: 10.14309/ctg.0000000000000134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Sempere LF, Azmi AS, Moore A. microRNA-based diagnostic and therapeutic applications in cancer medicine. Wiley Interdiscip Rev RNA 2021;:e1662. [PMID: 33998154 DOI: 10.1002/wrna.1662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Jani S, Ramirez MS, Tolmasky ME. Silencing Antibiotic Resistance with Antisense Oligonucleotides. Biomedicines 2021;9:416. [PMID: 33921367 DOI: 10.3390/biomedicines9040416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Huang J, Yu M, Yin W, Liang B, Li A, Li J, Li X, Zhao S, Liu F. Development of a novel RNAi therapy: Engineered miR-31 exosomes promoted the healing of diabetic wounds. Bioact Mater 2021;6:2841-53. [PMID: 33718666 DOI: 10.1016/j.bioactmat.2021.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Sen M, Bassetto M, Poulhes F, Zelphati O, Ueffing M, Arango-Gonzalez B. Efficient Ocular Delivery of VCP siRNA via Reverse Magnetofection in RHO P23H Rodent Retina Explants. Pharmaceutics 2021;13:225. [PMID: 33562020 DOI: 10.3390/pharmaceutics13020225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
26 Gupta A, Kafetzis KN, Tagalakis AD, Yu-Wai-Man C. RNA therapeutics in ophthalmology - translation to clinical trials. Exp Eye Res 2021;205:108482. [PMID: 33548256 DOI: 10.1016/j.exer.2021.108482] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Nourse J, Danckwardt S. A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies. Pharmacology & Therapeutics 2021;218:107676. [DOI: 10.1016/j.pharmthera.2020.107676] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Titze-de-Almeida SS, Brandão PRP, Faber I, Titze-de-Almeida R. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran. Mol Diagn Ther 2020;24:49-59. [PMID: 31701435 DOI: 10.1007/s40291-019-00434-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
29 Hall R, Alasmari A, Mozaffari S, Mahdipoor P, Parang K, Montazeri Aliabadi H. Peptide/Lipid-Associated Nucleic Acids (PLANAs) as a Multicomponent siRNA Delivery System. Mol Pharm 2021;18:986-1002. [PMID: 33496597 DOI: 10.1021/acs.molpharmaceut.0c00969] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. The growth of siRNA-based therapeutics: Updated clinical studies. Biochem Pharmacol 2021;189:114432. [PMID: 33513339 DOI: 10.1016/j.bcp.2021.114432] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
31 Freitag F, Wagner E. Optimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach. Adv Drug Deliv Rev 2021;168:30-54. [PMID: 32246984 DOI: 10.1016/j.addr.2020.03.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
32 Huang Z, Xu Y, Wan M, Zeng X, Wu J. miR-340: A multifunctional role in human malignant diseases. Int J Biol Sci 2021;17:236-46. [PMID: 33390846 DOI: 10.7150/ijbs.51123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
33 Adil MS, Khulood D, Somanath PR. Targeting Akt-associated microRNAs for cancer therapeutics. Biochem Pharmacol 2021;189:114384. [PMID: 33347867 DOI: 10.1016/j.bcp.2020.114384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Gebert M, Jaśkiewicz M, Moszyńska A, Collawn JF, Bartoszewski R. The Effects of Single Nucleotide Polymorphisms in Cancer RNAi Therapies. Cancers (Basel) 2020;12:E3119. [PMID: 33113880 DOI: 10.3390/cancers12113119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Krohn-Grimberghe M, Mitchell MJ, Schloss MJ, Khan OF, Courties G, Guimaraes PPG, Rohde D, Cremer S, Kowalski PS, Sun Y, Tan M, Webster J, Wang K, Iwamoto Y, Schmidt SP, Wojtkiewicz GR, Nayar R, Frodermann V, Hulsmans M, Chung A, Hoyer FF, Swirski FK, Langer R, Anderson DG, Nahrendorf M. Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic stem-cell niche. Nat Biomed Eng 2020;4:1076-89. [PMID: 33020600 DOI: 10.1038/s41551-020-00623-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
36 Zhou X, Pan Y, Li Z, Li H, Wu J, Ma Y, Guan Z, Yang Z. siRNA Packaged with Neutral Cytidinyl/Cationic/PEG Lipids for Enhanced Antitumor Efficiency and Safety In Vitro and In Vivo. ACS Appl Bio Mater 2020;3:6297-309. [PMID: 35021760 DOI: 10.1021/acsabm.0c00775] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Balachandran AA, Larcher LM, Chen S, Veedu RN. Therapeutically Significant MicroRNAs in Primary and Metastatic Brain Malignancies. Cancers (Basel) 2020;12:E2534. [PMID: 32906592 DOI: 10.3390/cancers12092534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Boumil EF, Castro N, Phillips AT, Chatterton JE, McCauley SM, Wolfson AD, Shmushkovich T, Ridilla M, Bernstein AM. USP10 Targeted Self-Deliverable siRNA to Prevent Scarring in the Cornea. Mol Ther Nucleic Acids 2020;21:1029-43. [PMID: 32829179 DOI: 10.1016/j.omtn.2020.07.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chakraborty C, Sharma AR, Sharma G, Lee SS. Therapeutic advances of miRNAs: A preclinical and clinical update. J Adv Res. 2021;28:127-138. [PMID: 33364050 DOI: 10.1016/j.jare.2020.08.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
40 Simberloff D. Maintenance management and eradication of established aquatic invaders. Hydrobiologia 2020;:1-22. [PMID: 32836349 DOI: 10.1007/s10750-020-04352-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
41 Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101. [PMID: 32561705 DOI: 10.1038/s41392-020-0207-x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 235] [Article Influence: 49.5] [Reference Citation Analysis]
42 Eringyte I, Zamarbide Losada JN, Powell SM, Bevan CL, Fletcher CE. Coordinated AR and microRNA regulation in prostate cancer. Asian J Urol 2020;7:233-50. [PMID: 32742925 DOI: 10.1016/j.ajur.2020.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Ben-Nun D, Buja LM, Fuentes F. Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics. Cardiovasc Pathol 2020;49:107243. [PMID: 32629211 DOI: 10.1016/j.carpath.2020.107243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
44 Jiang J, Zhang X, Tang Y, Li S, Chen J. Progress on ocular siRNA gene-silencing therapy and drug delivery systems. Fundam Clin Pharmacol 2021;35:4-24. [PMID: 32298491 DOI: 10.1111/fcp.12561] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
45 Titze-de-Almeida SS, Soto-Sánchez C, Fernandez E, Koprich JB, Brotchie JM, Titze-de-Almeida R. The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. Cells 2020;9:E841. [PMID: 32244357 DOI: 10.3390/cells9040841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
46 Waller P, Blann AD. Non-coding RNAs - A primer for the laboratory scientist. Br J Biomed Sci 2019;76:157-65. [PMID: 31594453 DOI: 10.1080/09674845.2019.1675847] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
47 Liang X, Li D, Leng S, Zhu X. RNA-based pharmacotherapy for tumors: From bench to clinic and back. Biomed Pharmacother 2020;125:109997. [PMID: 32062550 DOI: 10.1016/j.biopha.2020.109997] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
48 Krichevsky AM, Uhlmann EJ. Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond. Neurotherapeutics 2019;16:319-47. [PMID: 30644073 DOI: 10.1007/s13311-018-00702-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
49 Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol 2020;17:111-30. [PMID: 31900466 DOI: 10.1038/s41575-019-0230-y] [Cited by in Crossref: 209] [Cited by in F6Publishing: 193] [Article Influence: 104.5] [Reference Citation Analysis]
50 Bates M, Furlong F, Gallagher MF, Spillane CD, Mccann A, O'toole S, O'leary JJ. Too MAD or not MAD enough: The duplicitous role of the spindle assembly checkpoint protein MAD2 in cancer. Cancer Letters 2020;469:11-21. [DOI: 10.1016/j.canlet.2019.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
51 Martinez B, Reaser JK, Dehgan A, Zamft B, Baisch D, Mccormick C, Giordano AJ, Aicher R, Selbe S. Technology innovation: advancing capacities for the early detection of and rapid response to invasive species. Biol Invasions 2020;22:75-100. [DOI: 10.1007/s10530-019-02146-y] [Cited by in Crossref: 32] [Article Influence: 10.7] [Reference Citation Analysis]
52 Britton C, Laing R, Devaney E. Small RNAs in parasitic nematodes - forms and functions. Parasitology 2020;147:855-64. [PMID: 31843030 DOI: 10.1017/S0031182019001689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
53 de Paula Brandão PR, Titze-de-almeida SS, Titze-de-almeida R. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran. Mol Diagn Ther 2020;24:61-8. [DOI: 10.1007/s40291-019-00438-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
54 Gourvest M, Brousset P, Bousquet M. Long Noncoding RNAs in Acute Myeloid Leukemia: Functional Characterization and Clinical Relevance. Cancers (Basel) 2019;11:E1638. [PMID: 31653018 DOI: 10.3390/cancers11111638] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
55 Tesfaye AA, Azmi AS, Philip PA. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. Am J Pathol 2019;189:58-70. [PMID: 30558723 DOI: 10.1016/j.ajpath.2018.10.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
56 Wan TM, Iyer DN, Ng L. Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer. Histol Histopathol 2020;35:225-37. [PMID: 31617575 DOI: 10.14670/HH-18-171] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
57 Loy DM, Klein PM, Krzysztoń R, Lächelt U, Rädler JO, Wagner E. A microfluidic approach for sequential assembly of siRNA polyplexes with a defined structure-activity relationship. PeerJ Materials Science 2019;1:e1. [DOI: 10.7717/peerj-matsci.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kanbay M, Yerlikaya A, Sag AA, Ortiz A, Kuwabara M, Covic A, Wiecek A, Stenvinkel P, Afsar B. A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. Clin Kidney J 2019;12:861-70. [PMID: 31807301 DOI: 10.1093/ckj/sfz106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
59 Lee SC, Quinn A, Nguyen T, Venkatesh S, Quinn TP. A cross-cancer metastasis signature in the microRNA-mRNA axis of paired tissue samples. Mol Biol Rep 2019;46:5919-30. [PMID: 31410687 DOI: 10.1007/s11033-019-05025-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
60 Rock BM, Foti RS. Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities. Drug Metab Dispos 2019;47:1097-9. [PMID: 31399505 DOI: 10.1124/dmd.119.088708] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
61 Sakaue S, Hirata J, Maeda Y, Kawakami E, Nii T, Kishikawa T, Ishigaki K, Terao C, Suzuki K, Akiyama M, Suita N, Masuda T, Ogawa K, Yamamoto K, Saeki Y, Matsushita M, Yoshimura M, Matsuoka H, Ikari K, Taniguchi A, Yamanaka H, Kawaji H, Lassmann T, Itoh M, Yoshitomi H, Ito H, Ohmura K, R Forrest AR, Hayashizaki Y, Carninci P, Kumanogoh A, Kamatani Y, de Hoon M, Yamamoto K, Okada Y. Integration of genetics and miRNA-target gene network identified disease biology implicated in tissue specificity. Nucleic Acids Res 2018;46:11898-909. [PMID: 30407537 DOI: 10.1093/nar/gky1066] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
62 Hu B, Weng Y, Xia XH, Liang XJ, Huang Y. Clinical advances of siRNA therapeutics. J Gene Med 2019;21:e3097. [PMID: 31069898 DOI: 10.1002/jgm.3097] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 17.0] [Reference Citation Analysis]
63 Weidle UH, Birzele F, Nopora A. MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer. Cancer Genomics Proteomics 2019;16:99-119. [PMID: 30850362 DOI: 10.21873/cgp.20116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
64 Titze-de-Almeida R, Titze-de-Almeida SS, Ferreira NR, Fontanari C, Faccioli LH, Del Bel E. Suppressing nNOS Enzyme by Small-Interfering RNAs Protects SH-SY5Y Cells and Nigral Dopaminergic Neurons from 6-OHDA Injury. Neurotox Res 2019;36:117-31. [PMID: 31041676 DOI: 10.1007/s12640-019-00043-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
65 Mozaffari S, Bousoik E, Amirrad F, Lamboy R, Coyle M, Hall R, Alasmari A, Mahdipoor P, Parang K, Montazeri Aliabadi H. Amphiphilic Peptides for Efficient siRNA Delivery. Polymers (Basel) 2019;11:E703. [PMID: 30999603 DOI: 10.3390/polym11040703] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
66 Hussein HAM, Alfhili MA, Pakala P, Simon S, Hussain J, McCubrey JA, Akula SM. miRNAs and their roles in KSHV pathogenesis. Virus Res 2019;266:15-24. [PMID: 30951791 DOI: 10.1016/j.virusres.2019.03.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
67 Ganbold T, Han S, Hasi A, Baigude H. Receptor-mediated delivery of therapeutic RNA by peptide functionalized curdlan nanoparticles. International Journal of Biological Macromolecules 2019;126:633-40. [DOI: 10.1016/j.ijbiomac.2018.12.152] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
68 Wu KL, Tsai YM, Lien CT, Kuo PL, Hung AJ. The Roles of MicroRNA in Lung Cancer. Int J Mol Sci. 2019;20. [PMID: 30935143 DOI: 10.3390/ijms20071611] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 36.0] [Reference Citation Analysis]
69 Johannes L, Lucchino M. Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs. Nucleic Acid Ther 2018;28:178-93. [PMID: 29883296 DOI: 10.1089/nat.2017.0716] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
70 Kim MW, Jeong HY, Kang SJ, Jeong IH, Choi MJ, You YM, Im CS, Song IH, Lee TS, Lee JS, Lee A, Park YS. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer. Theranostics 2019;9:837-52. [PMID: 30809312 DOI: 10.7150/thno.30228] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 16.0] [Reference Citation Analysis]
71 Yang J. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert Rev Clin Pharmacol 2019;12:95-9. [PMID: 30644768 DOI: 10.1080/17512433.2019.1567326] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
72 Arruda DC, Gonzalez IJ, Finet S, Cordova L, Trichet V, Andrade GF, Hoffmann C, Bigey P, de Almeida Macedo WA, Da Silva Cunha A Jr, Malachias de Souza A, Escriou V. Modifying internal organization and surface morphology of siRNA lipoplexes by sodium alginate addition for efficient siRNA delivery. J Colloid Interface Sci 2019;540:342-53. [PMID: 30660791 DOI: 10.1016/j.jcis.2019.01.043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
73 Balmayor ER, Evans CH. RNA Therapeutics for Tissue Engineering. Tissue Engineering Part A 2019;25:9-11. [DOI: 10.1089/ten.tea.2018.0315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
74 Wang J, He X, Shen S, Cao Z, Yang X. ROS-Sensitive Cross-Linked Polyethylenimine for Red-Light-Activated siRNA Therapy. ACS Appl Mater Interfaces 2019;11:1855-63. [DOI: 10.1021/acsami.8b18697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
75 Cultrara CN, Shah S, Kozuch SD, Patel MR, Sabatino D. Solid phase synthesis and self-assembly of higher-order siRNAs and their bioconjugates. Chem Biol Drug Des 2019;93:999-1010. [PMID: 30480355 DOI: 10.1111/cbdd.13448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Hsu W, Sánchez-gómez P, Gomez-ibarlucea E, Ivanov DP, Rahman R, Grabowska AM, Csaba N, Alexander C, Garcia-fuentes M. Structure-Optimized Interpolymer Polyphosphazene Complexes for Effective Gene Delivery against Glioblastoma. Adv Therap 2019;2:1800126. [DOI: 10.1002/adtp.201800126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
77 Hung J, Miscianinov V, Sluimer JC, Newby DE, Baker AH. Targeting Non-coding RNA in Vascular Biology and Disease. Front Physiol 2018;9:1655. [PMID: 30524312 DOI: 10.3389/fphys.2018.01655] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
78 Louwies T, Ligon CO, Johnson AC, Greenwood-Van Meerveld B. Targeting epigenetic mechanisms for chronic visceral pain: A valid approach for the development of novel therapeutics. Neurogastroenterol Motil 2019;31:e13500. [PMID: 30393913 DOI: 10.1111/nmo.13500] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
79 O'shea J, Theile CS, Das R, Babu IR, Charisse K, Manoharan M, Maier MA, Zlatev I. An efficient deprotection method for 5′-[O,O-bis(pivaloyloxymethyl)]-(E)-vinylphosphonate containing oligonucleotides. Tetrahedron 2018;74:6182-6. [DOI: 10.1016/j.tet.2018.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
80 Horst CH, Schlemmer F, de Aguiar Montenegro N, Domingues ACM, Ferreira GG, da Silva Ribeiro CY, de Andrade RR, Del Bel Guimarães E, Titze-de-almeida SS, Titze-de-almeida R. Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats. Neurochem Res 2018;43:2132-40. [DOI: 10.1007/s11064-018-2638-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
81 Xiao Y, Shi K, Qu Y, Chu B, Qian Z. Engineering Nanoparticles for Targeted Delivery of Nucleic Acid Therapeutics in Tumor. Mol Ther Methods Clin Dev 2019;12:1-18. [PMID: 30364598 DOI: 10.1016/j.omtm.2018.09.002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 14.0] [Reference Citation Analysis]
82 Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I. An RNA toolbox for cancer immunotherapy. Nat Rev Drug Discov 2018;17:751-67. [DOI: 10.1038/nrd.2018.132] [Cited by in Crossref: 70] [Cited by in F6Publishing: 97] [Article Influence: 17.5] [Reference Citation Analysis]
83 Vaidya A, Roy A, Chaguturu R. How to rekindle drug discovery process through integrative therapeutic targeting? Expert Opin Drug Discov 2018;13:893-8. [PMID: 30146919 DOI: 10.1080/17460441.2018.1514010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
84 Dzmitruk V, Apartsin E, Ihnatsyeu-Kachan A, Abashkin V, Shcharbin D, Bryszewska M. Dendrimers Show Promise for siRNA and microRNA Therapeutics. Pharmaceutics 2018;10:E126. [PMID: 30096839 DOI: 10.3390/pharmaceutics10030126] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
85 Zacchigna S, Giacca M. The global role of biotechnology for non communicable disorders. J Biotechnol 2018;283:115-9. [PMID: 30077584 DOI: 10.1016/j.jbiotec.2018.07.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
86 Titze de Almeida SS, Horst CH, Soto-Sánchez C, Fernandez E, Titze de Almeida R. Delivery of miRNA-Targeted Oligonucleotides in the Rat Striatum by Magnetofection with Neuromag®. Molecules 2018;23:E1825. [PMID: 30041414 DOI: 10.3390/molecules23071825] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
87 Martin JL, Gruszczyk AV, Beach TE, Murphy MP, Saeb-Parsy K. Mitochondrial mechanisms and therapeutics in ischaemia reperfusion injury. Pediatr Nephrol 2019;34:1167-74. [PMID: 29860579 DOI: 10.1007/s00467-018-3984-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
88 Oberemok VV, Laikova KV, Repetskaya AI, Kenyo IM, Gorlov MV, Kasich IN, Krasnodubets AM, Gal'chinsky NV, Fomochkina II, Zaitsev AS, Bekirova VV, Seidosmanova EE, Dydik KI, Meshcheryakova AO, Nazarov SA, Smagliy NN, Chelengerova EL, Kulanova AA, Deri K, Subbotkin MV, Useinov RZ, Shumskykh MN, Kubyshkin AV. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey. Molecules 2018;23:E1302. [PMID: 29844255 DOI: 10.3390/molecules23061302] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
89 Nakano M, Nakajima M. Current knowledge of microRNA-mediated regulation of drug metabolism in humans. Expert Opin Drug Metab Toxicol 2018;14:493-504. [PMID: 29718737 DOI: 10.1080/17425255.2018.1472237] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
90 Lundstrom K. Epigenetics, Nutrition, Disease and Drug Development. Curr Drug Discov Technol 2019;16:386-91. [PMID: 29692252 DOI: 10.2174/1570163815666180419154954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Arriaga-Canon C, De La Rosa-Velázquez IA, González-Barrios R, Montiel-Manríquez R, Oliva-Rico D, Jiménez-Trejo F, Cortés-González C, Herrera LA. The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer. Oncotarget 2018;9:20872-90. [PMID: 29755696 DOI: 10.18632/oncotarget.25038] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
92 Resende FFB, Titze-de-Almeida SS, Titze-de-Almeida R. Function of neuronal nitric oxide synthase enzyme in temozolomide-induced damage of astrocytic tumor cells. Oncol Lett 2018;15:4891-9. [PMID: 29552127 DOI: 10.3892/ol.2018.7917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
93 Parmar RG, Brown CR, Matsuda S, Willoughby JLS, Theile CS, Charissé K, Foster DJ, Zlatev I, Jadhav V, Maier MA, Egli M, Manoharan M, Rajeev KG. Facile Synthesis, Geometry, and 2'-Substituent-Dependent in Vivo Activity of 5'-(E)- and 5'-(Z)-Vinylphosphonate-Modified siRNA Conjugates. J Med Chem 2018;61:734-44. [PMID: 29376650 DOI: 10.1021/acs.jmedchem.7b01147] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
94 Chen L, Dzakah EE, Shan G. Targetable long non-coding RNAs in cancer treatments. Cancer Lett 2018;418:119-24. [PMID: 29341880 DOI: 10.1016/j.canlet.2018.01.042] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 12.0] [Reference Citation Analysis]
95 Nagaya Y, Kitamura Y, Shibata A, Ikeda M, Akao Y, Kitade Y. Introduction of 2- O -benzyl abasic nucleosides to the 3′-overhang regions of siRNAs greatly improves nuclease resistance. Bioorganic & Medicinal Chemistry Letters 2017;27:5454-6. [DOI: 10.1016/j.bmcl.2017.10.070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
96 Lv W, Fan F, Wang Y, Gonzalez-Fernandez E, Wang C, Yang L, Booz GW, Roman RJ. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiol Genomics 2018;50:20-34. [PMID: 29127220 DOI: 10.1152/physiolgenomics.00039.2017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
97 Do H, Sharma M, El-Sayed NS, Mahdipoor P, Bousoik E, Parang K, Montazeri Aliabadi H. Difatty Acyl-Conjugated Linear and Cyclic Peptides for siRNA Delivery. ACS Omega 2017;2:6939-57. [PMID: 30023535 DOI: 10.1021/acsomega.7b00741] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
98 Krhac Levacic A, Morys S, Wagner E. Solid-phase supported design of carriers for therapeutic nucleic acid delivery. Biosci Rep 2017;37:BSR20160617. [PMID: 28963371 DOI: 10.1042/BSR20160617] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
99 He Z, Jin Z, Zhan M, Qin Z, Li Z, Xu T. Advances in quantum dot-mediated siRNA delivery. Chinese Chemical Letters 2017;28:1851-6. [DOI: 10.1016/j.cclet.2017.07.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
100 Moghimi SM, Wagner E. Nanoparticle Technology: Having Impact, but Needing Further Optimization. Mol Ther 2017;25:1461-3. [PMID: 28625572 DOI: 10.1016/j.ymthe.2017.06.007] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]